During the IDWeek conference held in Boston earlier this month, presentations on Climate Change were spread throughout the program. Some talks were on the direct effects of weather on infectious agents. Others discussed what healthcare workers could do to mitigate the effects of climate change, from antibiotic stewardship to decarbonization of day to day operations. Read More
Vyne Therapeutics Inc. has released promising new preclinical data on its oral small-molecule BD2-selective BET inhibitor, VYN-202, in preclinical models of psoriasis and rheumatoid arthritis. In a well-established model, a psoriasis phenotype was induced in BALB-C mice, and treatment was administered intraperitoneally with either VYN-202, the allosteric TYK2 inhibitor Sotykto (deucravacitinib, Bristol Myers Squibb Co.) or placebo. Read More
Heterozygous familial hypercholesterolemia (HeFH) is caused by mutations in the LDL receptor gene, resulting in unusually high levels of low-density lipoprotein (LDL-C) in serum. Researchers from Epigenic Therapeutics Co. Ltd. presented the discovery of an epigenetic modulation therapeutic, EPI-001, for HeFH. Read More
Researchers from Hokkaido University (Japan) and colleagues have identified 2-thiouridine (s2U) as a broad-spectrum antiviral ribonucleoside analogue, by phenotypic screening of a library of 753 nucleoside analogues for antiviral effects. s2U showed antiviral activity against several ssRNA+ viruses, including DENV, SARS-CoV-2 and its variants of concern. Read More
Jiangsu Hengrui Medicine Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented transcriptional coactivator YAP1/transcriptional enhancer factor (TEAD) interaction inhibitors reported to be useful for the treatment of cancer. Read More
Investigators from Biomarin Pharmaceutical Inc. have presented the first preclinical data for BMN-293, a novel adeno-associated virus (AAV) gene transfer vector carrying the MYBPC3 gene. MYBPC3 mutations can cause hypertrophic cardiomyopathy (HCM), a heart medical condition characterized by an abnormally thick myocardium, which makes it more difficult for the heart to pump blood. Read More
VBI Vaccines Inc. has announced the development of its next-generation mRNA-launched enveloped virus-like particle (eVLP) technology, which expands on the company's current proprietary eVLP technology by coding the particles in messenger RNA (mRNA). Read More
Researchers from Neophore Ltd. presented the discovery and preclinical evaluation of NP-1867, a small molecule inhibitor of DNA mismatch repair (MMR) protein PMS2, being developed for the treatment of cancer. Read More
Researchers at Suzhou Vigonvita Life Sciences Co. Ltd. have identified N-substituted quinolinones and their prodrugs acting as 5-HT1A and dopamine D3 receptor (DRD3) agonists, 5-HT2A and dopamine D2 receptor antagonists and serotonin transporter (SERT) inhibitors. Read More
Duo Oncology Inc. has been awarded a Small Business Technology Transfer grant by the National Cancer Institute (NCI) to support the development of DUO-307, a combination nanomedicine that delivers cytotoxic polymer conjugated gemcitabine (PGEM) and an immune modulating chemokine receptor type 2 antagonist (CCR2a) to tumor tissue. Read More
Beigene Ltd. has disclosed new Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1) inhibitors reported to be useful for the treatment of cancer, viral infections, age-related issues, neurological, immunological and inflammatory disorders. Read More
A team at Berrybio (Shanghai) Ltd. has prepared proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding moiety covalently linked to focal adhesion kinase (FAK)-targeting moiety through a linker. Read More
Approximately 2% to 6% of familiar dilated cardiomyopathy (DCM) cases are caused by inherited mutations in the RBM20 gene, which encodes the RNA binding motif 20 (RBM20), a splicing factor that regulates the splicing of several targets involved in the regulation of sarcomeric structure and calcium handling in the myocardium. Read More
S-Adenosylmethionine synthase isoform type-2 (Mat2A) inhibitors have been described in a Shouyao Holdings (Beijing) Co. Ltd. patent to be useful for the treatment of cancer. Read More
Additional early-stage research and drug discovery news in brief, from: Aviadobio, Boundless Bio, Maia Biotechnology, Meiragtx, Prime Medicine, Revelation Biosciences, Seraxis. Read More
